AnaptysBio, Inc. Common Stock (ANAB) Stock Price, Quote & AI Analysis

Live ANAB stock price, real-time charts, AI-powered analysis, technical analysis, earnings insights, and market sentiment for AnaptysBio, Inc. Common Stock.

TradeVae provides AI-driven analysis and real-time market intelligence for AnaptysBio, Inc. Common Stock (ANAB), including price action, technical indicators, earnings performance, analyst sentiment, and risk-aware market context.

A
ANAB
AnaptysBio, Inc. Common Stock
real-time
$0.00 +0.00 (+0.00%)
Open
0.000000
High
0.000000
Low
0.000000
Volume
0
VWAP
-
Market Cap
$1,642,382,441.07
52W Range
$12.53 - $72.36
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Upcoming Earnings
Nov 2, 2026 Q3
After Hours
EPS Estimate: $-0.0826
Revenue Estimate: $40,351,200.00
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

AnaptysBio, Inc. Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

AnaptysBio, Inc. Common Stock Overview

Company information

Company Overview

AnaptysBio, Inc. is a clinical-stage biotechnology company, which engages in delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The firm’s product pipeline includes Rosnilimab, ANB033, ANB101, Jemperli, and Imsidolimab. It operates through the Biopharma and Royalty Management segments. The Biopharma segment focuses on the development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases. The Royalty Management segment manages the financial collaboration for Jemperli with GSK and for imsidolimab with Vanda. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Company Details
Market Cap
$1.77B
Shares Outstanding
30,607,202
Weighted Shares Outstanding
29,608,481
CEO
Daniel R. Faga
Address
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA, 92121
Employees
104
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
XNAS

Technical Indicators

Key technical analysis metrics and indicators

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

AnaptysBio, Inc. Common Stock Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...